ANNEX 2

Country profiles
FOR 30 HIGH TB BURDEN COUNTRIES
high TB burden countries
20 based on absolute number

of incident cases

high TB burden countries

10 based on severity of disease

burden (incidence per capita)
A TB patient takes his treatment at a health clinic in the Western Cape, South Africa
SYDELLE WILLOW SMITH / MSF
 Angola POPULATION 2016 29 MILLION
Estimates of TB burden,a 20 16 120

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 18 (1029) 64 (3699)
Mortality (HIV+TB only) 6.9 (3.412) 24 (1241) 80
Incidence (includes HIV+TB) 107 (66156) 370 (230543)
Incidence (HIV+TB only) 18 (8.530) 61 (29104)
Incidence (MDR/RR-TB)b 4.3 (1.47.3) 15 (4.825) 40

Estimated TB incidence by age and sex (thousands),a 20 16

014 years > 14 years Total
0
Females 5.1 (2.97.2) 35 (2050) 40 (2358)
2000 2004 2008 2012 2016
Males 5.8 (3.38.3) 60 (3586) 66 (3894)
Total 11 (6.316) 96 (55136) 107 (66156)
600

(Rate per 100 000 population per year)

TB case notifications, 20 16
Total cases notified 60 916
Total new and relapse 59 513 400

Incidence
% tested with rapid diagnostics at time of diagnosis <1%
% with known HIV status 46%
% pulmonary 93% 200
% bacteriologically confirmed among pulmonary 54%

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 56% (3890) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs
Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.25 (0.130.4) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016

Number (%) 65

Patients with known HIV-status who are HIV-positive 2 765 10% 5564
on antiretroviral therapy
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534
Estimated MDR/RR-TB cases among 2 600
notified pulmonary TB cases (7904 400) 1524

Estimated % of TB cases with 014

MDR/RR-TB 2.6% (0.15.1) 18% (0.136)
% notified tested for 3000 2000 1000 0 1000 2000 3000 4000 5000
rifampicin resistance <1% 4% 452
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 0
Laboratory-confirmed cases MDR/RR-TB: 167, XDR-TB: 0
Patients started on treatmentd MDR/RR-TB: 334, XDR-TB: 0 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 60

Previously treated cases, excluding relapse, registered in 2015

40
HIV-positive TB cases registered in 2015
MDR/RR-TB cases started on second-line treatment in 2014 43% 249
20
XDR-TB cases started on second-line treatment in 2014 0

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 25
National TB budget (US$ millions) 14
Funding source: 29% domestic, 19% international, 52% unfunded 20
Total budget (US$ millions)

15

10

5
Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

156 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

5 50
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

10
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0
2000 2015 2000 2015

10 60
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

50
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population) 0
2000 2015 2000 2015

500 8000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

50 70
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

100
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 157
 Bangladesh POPULATION 2016 163 MILLION
Estimates of TB burden,a 20 16 120

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 66 (4394) 40 (2658)
Mortality (HIV+TB only) 0.18 (0.0860.3) 0.11 (0.050.18) 80
Incidence (includes HIV+TB) 360 (262474) 221 (161291)
Incidence (HIV+TB only) 0.5 (0.250.84) 0.31 (0.150.52)
Incidence (MDR/RR-TB)b 8.8 (4.813) 5.4 (2.97.8) 40

Estimated TB incidence by age and sex (thousands),a 20 16

014 years > 14 years Total 0
Females 17 (1222) 112 (79144) 129 (91167) 2000 2004 2008 2012 2016
Males 19 (1425) 212 (150275) 232 (164300)
Total 36 (2647) 324 (229419) 360 (262474)
300

(Rate per 100 000 population per year)

TB case notifications, 20 16
Total cases notified 223 921
Total new and relapse 222 248 200

Incidence
% tested with rapid diagnostics at time of diagnosis
% with known HIV status 2%
% pulmonary 80% 100
% bacteriologically confirmed among pulmonary 72%

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 62% (4785) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs
Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.19 (0.110.29) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016

Number (%) 65

Patients with known HIV-status who are HIV-positive 87 2% 5564

on antiretroviral therapy 69 79%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534
Estimated MDR/RR-TB cases among 5 300
notified pulmonary TB cases (3 5007 200) 1524

Estimated % of TB cases with 014

MDR/RR-TB 1.6% (0.592.6) 29% (2236)
% notified tested for 20 000 10 000 0 10 000 20 000 30 000
rifampicin resistance 16% 62% 43 991
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 139
Laboratory-confirmed cases MDR/RR-TB: 969, XDR-TB: 9
Patients started on treatmentd MDR/RR-TB: 918, XDR-TB: 8 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 93% 206 907 60

Previously treated cases, excluding relapse, registered in 2015 86% 2 518

40
HIV-positive TB cases registered in 2015 68% 72
MDR/RR-TB cases started on second-line treatment in 2014 74% 946
20
XDR-TB cases started on second-line treatment in 2014 0% 3

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment 17% (1619) HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 100
National TB budget (US$ millions) 85
Funding source: 7% domestic, 51% international, 43% unfunded 80
Total budget (US$ millions)

60

40

20
Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

158 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

1 50
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

15 25
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males 0 (% of population) 0
2000 2015 2000 2015

5 40
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

100 20
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males 0 (% of population) 0
2000 2015 2000 2015

100 5000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

100 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
0 0
health) 2000 2015 2000 2015

100
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 159
 Brazil POPULATION 2016 208 MILLION
Estimates of TB burden,a 20 16 8

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 5.4 (4.95.9) 2.6 (2.32.9) 6
Mortality (HIV+TB only) 1.9 (1.42.4) 0.9 (0.661.2)
Incidence (includes HIV+TB) 87 (74100) 42 (3648)
4
Incidence (HIV+TB only) 11 (9.113) 5.2 (4.46.2)
Incidence (MDR/RR-TB)b 2.4 (1.92.8) 1.1 (0.91.4)
2
Estimated TB incidence by age and sex (thousands),a 20 16
014 years > 14 years Total 0
Females 4.9 (4.25.7) 24 (2027) 29 (2433) 2000 2004 2008 2012 2016
Males 5.5 (4.76.3) 53 (4561) 58 (5067)
Total 10 (8.912) 76 (6588) 87 (74100)

(Rate per 100 000 population per year)

60
TB case notifications, 20 16
Total cases notified 82 676
Total new and relapse 75 444
40

Incidence
% tested with rapid diagnostics at time of diagnosis 21%
% with known HIV status 76%
% pulmonary 87% 20
% bacteriologically confirmed among pulmonary 72%

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 87% (75100) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.08 (0.070.1) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016
65
Number (%)
Patients with known HIV-status who are HIV-positive 7 381 13% 5564
on antiretroviral therapy 3 126 42%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534

Estimated MDR/RR-TB cases among 1 900
1524
notified pulmonary TB cases (1 5002 400)
Estimated % of TB cases with 014
MDR/RR-TB 1.5% (1.11.9) 8% (5.111)
% notified tested for 6000 4000 2000 0 2000 4000 6000 8000 10 000 12 000
rifampicin resistance 26% 35% 22 667
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 165
Laboratory-confirmed cases MDR/RR-TB: 990, XDR-TB: 10
Patients started on treatmentd MDR/RR-TB: 653, XDR-TB: 10 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 71% 74 064 60

Previously treated cases, excluding relapse, registered in 2015 38% 6 856

40
HIV-positive TB cases registered in 2015 49% 7 516
MDR/RR-TB cases started on second-line treatment in 2014 52% 793
20
XDR-TB cases started on second-line treatment in 2014 36% 72

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 100
National TB budget (US$ millions) 67
Funding source: 81% domestic, <1% international, 19% unfunded 80
Total budget (US$ millions)

60

40

20
Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

160 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

1 20
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

10 70
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

10 20
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

40 100
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

2000 20 000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

50 100
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

50
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 161
 China POPULATION 2016 1 404 MILLION
Estimates of TB burden,a 20 16 10

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)
8

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 50 (3470) 3.6 (2.45)
Mortality (HIV+TB only) 1.8 (0.73.4) 0.13 (0.050.24)
6
Incidence (includes HIV+TB) 895 (7661 030) 64 (5574)
Incidence (HIV+TB only) 11 (6.915) 0.76 (0.491.1)
4
Incidence (MDR/RR-TB)b 73 (5689) 5.2 (46.4)

2
Estimated TB incidence by age and sex (thousands),a 20 16
014 years > 14 years Total 0
Females 47 (4054) 245 (208281) 292 (248336) 2000 2004 2008 2012 2016
Males 53 (4561) 550 (468633) 603 (513694)
Total 100 (85115) 795 (676914) 895 (7661 030)
150

(Rate per 100 000 population per year)

TB case notifications, 20 16
Total cases notified 783 842
Total new and relapse 778 493 100

Incidence
% tested with rapid diagnostics at time of diagnosis
% with known HIV status 43%
% pulmonary 95% 50
% bacteriologically confirmed among pulmonary 31%

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 87% (75100) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs
Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.06 (0.040.08) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016

Number (%) 65

Patients with known HIV-status who are HIV-positive 4 612 1% 5564

on antiretroviral therapy 4 051 88%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534
Estimated MDR/RR-TB cases amon 58 000
notified pulmonary TB cases (47 00069 000) 1524

Estimated % of TB cases with 014

MDR/RR-TB 7.1% (5.68.7) 24% (2028)
% notified tested for 60 000 30 000 0 30 000 60 000 90 000 120 000
rifampicin resistance 13% 55% 118 219
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs
Laboratory-confirmed cases MDR/RR-TB: 10 898, XDR-TB: 525
Patients started on treatmentd MDR/RR-TB: 5 405, XDR-TB: 265 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 94% 798 281 60

Previously treated cases, excluding relapse, registered in 2015 83% 5 739

40
HIV-positive TB cases registered in 2015 87% 2 444
MDR/RR-TB cases started on second-line treatment in 2014 41% 2 846
20
XDR-TB cases started on second-line treatment in 2014 32% 135

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 400
National TB budget (US$ millions) 384
Funding source: 96% domestic, 3% international, 1% unfunded
Total budget (US$ millions)

300

200

100

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

162 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

50
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
(% of population) 0
2000 2015 2000 2015

10
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0
2000 2015 2000 2015

20 20
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

100 100
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

1000 15 000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

100 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

50
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 163
 Democratic Peoples Republic of Korea POPULATION 2016 25 MILLION
Estimates of TB burden,a 20 16 300

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 11 (6.816) 43 (2763)
Mortality (HIV+TB only) 0.051 (0.0230.089) 0.2 (0.090.35) 200
Incidence (includes HIV+TB) 130 (113148) 513 (446584)
Incidence (HIV+TB only) 0.28 (0.140.46) 1.1 (0.551.8)
Incidence (MDR/RR-TB)b 5.7 (3.28.1) 22 (1332) 100

Estimated TB incidence by age and sex (thousands),a 20 16

014 years > 14 years Total 0
Females 6.9 (5.97.8) 27 (2330) 34 (2938) 2000 2004 2008 2012 2016
Males 7.7 (6.78.7) 89 (77101) 97 (84110)
Total 15 (1317) 116 (100131) 130 (113148)

(Rate per 100 000 population per year)

TB case notifications, 20 16 600

Total cases notified 120 323

Total new and relapse 112 606
400

Incidence
% tested with rapid diagnostics at time of diagnosis
% with known HIV status
% pulmonary 81% 200
% bacteriologically confirmed among pulmonary 50%

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 87% (7699) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.08 (0.050.12) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016
65
Number (%)
Patients with known HIV-status who are HIV-positive 0 5564
on antiretroviral therapy
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534

Estimated MDR/RR-TB cases among 4 600
1524
notified pulmonary TB cases (2 3006 900)
Estimated % of TB cases with 014
MDR/RR-TB 2.2% (0.513.9) 16% (5.827)
% notified tested for 10 000 5000 0 5000 10 000 15 000 20 000
rifampicin resistance 0% 8% 1 394
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 0
Laboratory-confirmed cases MDR/RR-TB: 935, XDR-TB: 0
Patients started on treatmentd MDR/RR-TB: 814, XDR-TB: 19 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
60
New and relapse cases registered in 2015 90% 112 820
Previously treated cases, excluding relapse, registered in 2015 82% 7 882
40
HIV-positive TB cases registered in 2015 0
MDR/RR-TB cases started on second-line treatment in 2014 91% 212
20
XDR-TB cases started on second-line treatment in 2014 0

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment 100% (99100) HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 30
National TB budget (US$ millions) 27
Funding source: 20% domestic, 30% international, 49% unfunded
Total budget (US$ millions)

20

10

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

164 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

HIV prevalence Population

(% of population aged living below the
1549 years) international
poverty line
(% of population)
2000 2015 2000 2015

8
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0
2000 2015 2000 2015

8 50
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

10
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population) 0
2000 2015 2000 2015

Health GDP per capita,

expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
2000 2015 2000 2015

Out-of- GINI index

pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 2000 2015 2000 2015

Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 165
 Democratic Republic of the Congo POPULATION 2016 79 MILLION
Estimates of TB burden,a 20 16 120

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 53 (3180) 67 (39101)
Mortality (HIV+TB only) 8.5 (415) 11 (5.119) 80
Incidence (includes HIV+TB) 254 (165363) 323 (209461)
Incidence (HIV+TB only) 20 (1329) 26 (1737)
Incidence (MDR/RR-TB)b 7.6 (3.911) 9.7 (4.915) 40

Estimated TB incidence by age and sex (thousands),a 20 16

014 years > 14 years Total 0
Females 15 (9.121) 82 (50114) 97 (59134) 2000 2004 2008 2012 2016
Males 17 (1024) 141 (86196) 158 (96220)
Total 32 (1944) 222 (135310) 254 (165363)
500

(Rate per 100 000 population per year)

TB case notifications, 20 16
400
Total cases notified 132 515
Total new and relapse 130 596
300

Incidence
% tested with rapid diagnostics at time of diagnosis
% with known HIV status 54%
200
% pulmonary 82%
% bacteriologically confirmed among pulmonary 81% 100

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 51% (3679) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs
Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.25 (0.130.4) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016

Number (%) 65
Patients with known HIV-status who are HIV-positive 8 344 12% 5564
on antiretroviral therapy 6 241 75%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc
2534
Estimated MDR/RR-TB cases among 3 600
notified pulmonary TB cases (2 3005 000) 1524
Estimated % of TB cases with 014
MDR/RR-TB 2.2% (13.5) 17% (9.624)
% notified tested for 15 000 10 000 5000 0 5000 10 000 15 000 20 000
rifampicin resistance 2% 6% 13 273
MDR/RR-TB cases tested for resistance to second-line drugs 223 Females Males

Laboratory-confirmed cases MDR/RR-TB: 709, XDR-TB: 39

Patients started on treatmentd MDR/RR-TB: 637, XDR-TB: 15 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New cases registered in 2015 89% 111 774 60
Previously treated cases registered in 2015 77% 5 399
HIV-positive TB cases registered in 2015 40
MDR/RR-TB cases started on second-line treatment in 2014 75% 448
XDR-TB cases started on second-line treatment in 2014 0 20

TB preventive treatment, 20 16 0
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed New cases Previously treated cases
TB cases on preventive treatment 6.3% (5.86.9) HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17
National TB budget (US$ millions) 57 60
Funding source: 3% domestic, 48% international, 49% unfunded
Total budget (US$ millions)

40

20

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

166 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

5 100
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

8 20
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

10
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0
! females ! males 2000 2015 2000 2015

10
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
2000 2015 0
2000 2015

50 1000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

100 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

100
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 167
 Ethiopia POPULATION 2016 102 MILLION
Estimates of TB burden,a 20 16 200

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 26 (1637) 25 (1636) 150
Mortality (HIV+TB only) 4 (2.75.4) 3.9 (2.65.3)
Incidence (includes HIV+TB) 182 (128245) 177 (125239)
100
Incidence (HIV+TB only) 14 (9.619) 13 (9.418)
Incidence (MDR/RR-TB)b 5.8 (3.18.5) 5.7 (38.3)
50
Estimated TB incidence by age and sex (thousands),a 20 16
014 years > 14 years Total 0
Females 11 (7.515) 70 (4893) 81 (55108) 2000 2004 2008 2012 2016
Males 12 (8.517) 88 (60116) 100 (68133)
Total 24 (1631) 158 (107209) 182 (128245)

(Rate per 100 000 population per year)

TB case notifications, 20 16 600

Total cases notified 127 407

Total new and relapse 125 836
400

Incidence
% tested with rapid diagnostics at time of diagnosis
% with known HIV status 81%
% pulmonary 68% 200
% bacteriologically confirmed among pulmonary 55%

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 69% (5198) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.17 (0.10.25) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016
65
Number (%)
Patients with known HIV-status who are HIV-positive 7 843 8% 5564
on antiretroviral therapy 6 929 88%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534

Estimated MDR/RR-TB cases among 2 900
1524
notified pulmonary TB cases (1 8004 000)
Estimated % of TB cases with 014
MDR/RR-TB 2.7% (1.54) 14% (3.625)
% notified tested for 20 000 15 000 10 000 5000 0 5000 10 000 15 000 20 000
rifampicin resistance 42% 100% 56 509
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 28
Laboratory-confirmed cases MDR/RR-TB: 700, XDR-TB: 2
Patients started on treatmentd MDR/RR-TB: 700, XDR-TB: 2 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New cases registered in 2015 84% 132 296 60

Previously treated cases registered in 2015

40
HIV-positive TB cases registered in 2015
MDR/RR-TB cases started on second-line treatment in 2014 70% 557
20
XDR-TB cases started on second-line treatment in 2014

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment 52%
% of children (aged < 5) household contacts of bacteriologically-confirmed New cases Previously treated cases
TB cases on preventive treatment HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 150
National TB budget (US$ millions) 84
Funding source: 11% domestic, 45% international, 43% unfunded
Total budget (US$ millions)

100

50

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

168 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

50
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
(% of population) 0
2000 2015 2000 2015

10 20
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

5 100
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

20 5
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

100 2000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

50 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

100
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 169
 India POPULATION 2016 1 324 MILLION
Estimates of TB burden,a 20 16 80

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 423 (324534) 32 (2440) 60
Mortality (HIV+TB only) 12 (6.619) 0.92 (0.51.5)
Incidence (includes HIV+TB) 2 790 (1 4404 570) 211 (109345)
40
Incidence (HIV+TB only) 87 (56125) 6.6 (4.39.4)
Incidence (MDR/RR-TB)b 147 (95199) 11 (7.215)
20
Estimated TB incidence by age and sex (thousands),a 20 16
014 years > 14 years Total 0
Females 107 (47167) 897 (3911 400) 1 000 (4371 570) 2000 2004 2008 2012 2016
Males 120 (52188) 1 660 (7252 600) 1 780 (7782 790)
Total 227 (99355) 2 560 (1 1204 010) 2 790 (1 4404 570)
500

(Rate per 100 000 population per year)

TB case notifications, 20 16
400
Total cases notified 1 936 158
Total new and relapse 1 763 876 300

Incidence
% tested with rapid diagnostics at time of diagnosis 17%
% with known HIV status 72% 200
% pulmonary 84%
% bacteriologically confirmed among pulmonary 63% 100

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 63% (39120) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs
Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.17 (0.090.27) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016

Number (%) 65

Patients with known HIV-status who are HIV-positive 39 815 3% 5564

on antiretroviral therapy 39 123 98%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534
Estimated MDR/RR-TB cases among 84 000
notified pulmonary TB cases (72 00095 000) 1524

Estimated % of TB cases with 014

MDR/RR-TB 2.8% (23.5) 12% (1013)
% notified tested for 180 000 90 000 0 90 000 180 000 270 000
rifampicin resistance 20% 67% 580 438
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 22 492
Laboratory-confirmed cases MDR/RR-TB: 37 258, XDR-TB: 2 464
Patients started on treatmentd MDR/RR-TB: 32 914, XDR-TB: 2 475 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 72% 1 656 233 60

Previously treated cases, excluding relapse, registered in 2015 66% 69 823

40
HIV-positive TB cases registered in 2015 78% 44 191
MDR/RR-TB cases started on second-line treatment in 2014 46% 22 524
20
XDR-TB cases started on second-line treatment in 2014 29% 1 397

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment 5%
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment 1.9% (1.72) HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 600
National TB budget (US$ millions) 525
Funding source: 74% domestic, 26% international, 0% unfunded
Total budget (US$ millions)

400

200

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding.
a
Ranges represent uncertainty intervals. Estimates of TB incidence and mortality for India are interim in 0
nature, pending results from the national TB prevalence survey planned for 2018/2019. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

170 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

50
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
(% of population) 0
2000 2015 2000 2015

10 50
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

5 30
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

50 50
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

300 8000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

100 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

50
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 171
 Indonesia POPULATION 2016 261 MILLION
Estimates of TB burden,a 20 16 80

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 110 (75152) 42 (2958) 60
Mortality (HIV+TB only) 13 (6.223) 5.1 (2.48.7)
Incidence (includes HIV+TB) 1 020 (6601 460) 391 (253558)
40
Incidence (HIV+TB only) 45 (2178) 17 (830)
Incidence (MDR/RR-TB)b 32 (1945) 12 (7.317)
20
Estimated TB incidence by age and sex (thousands),a 20 16
014 years > 14 years Total 0
Females 28 (1739) 294 (179410) 323 (196449) 2000 2004 2008 2012 2016
Males 32 (1944) 666 (405928) 698 (424972)
Total 60 (3683) 961 (5841 340) 1 020 (6601 460)

(Rate per 100 000 population per year)

600
TB case notifications, 20 16
Total cases notified 360 565
Total new and relapse 358 608
400

Incidence
% tested with rapid diagnostics at time of diagnosis <1%
% with known HIV status 14%
% pulmonary 92% 200
% bacteriologically confirmed among pulmonary 59%

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 35% (2554) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.13 (0.070.19) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016
65
Number (%)
Patients with known HIV-status who are HIV-positive 4 330 9% 5564
on antiretroviral therapy 1 228 28%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534

Estimated MDR/RR-TB cases among 11 000
1524
notified pulmonary TB cases (8 80013 000)
Estimated % of TB cases with 014
MDR/RR-TB 2.8% (2.23.5) 16% (1020)
% notified tested for 30 000 20 000 10 000 0 10 000 20 000 30 000 40 000
rifampicin resistance 2% 176% 26 973
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 1 060
Laboratory-confirmed cases MDR/RR-TB: 2 720, XDR-TB: 37
Patients started on treatmentd MDR/RR-TB: 1 879, XDR-TB: 52 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
60
New and relapse cases registered in 2015 85% 331 703
Previously treated cases, excluding relapse, registered in 2015 67% 1 859
40
HIV-positive TB cases registered in 2015 60% 3 634
MDR/RR-TB cases started on second-line treatment in 2014 51% 1 271
20
XDR-TB cases started on second-line treatment in 2014 13% 30

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment 2%
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment 1.5% (1.31.6) HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 200
National TB budget (US$ millions) 185
Funding source: 29% domestic, 18% international, 53% unfunded
Total budget (US$ millions)

150

100

50

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

172 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

1 50
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

10 100
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

2 30
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

100 100
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

500 15 000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

100 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

50
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 173
 Kenya POPULATION 2016 48 MILLION
Estimates of TB burden,a 20 16 150

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 29 (1645) 60 (3393)
Mortality (HIV+TB only) 24 (1436) 50 (3075) 100
Incidence (includes HIV+TB) 169 (103250) 348 (213516)
Incidence (HIV+TB only) 53 (3279) 109 (66162)
Incidence (MDR/RR-TB)b 3 (1.64.4) 6.2 (3.29.1) 50

Estimated TB incidence by age and sex (thousands),a 20 16

014 years > 14 years Total 0
Females 10 (5.915) 46 (2665) 56 (3180) 2000 2004 2008 2012 2016
Males 12 (6.717) 101 (57145) 113 (64162)
Total 22 (1332) 147 (83211) 169 (103250)
1000

(Rate per 100 000 population per year)

TB case notifications, 20 16
800
Total cases notified 77 376
Total new and relapse 76 335
600

Incidence
% tested with rapid diagnostics at time of diagnosis 26%
% with known HIV status 96%
400
% pulmonary 83%
% bacteriologically confirmed among pulmonary 70% 200

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 45% (3174) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs
Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.33 (0.170.51) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016

Number (%) 65
Patients with known HIV-status who are HIV-positive 22 911 31% 5564
on antiretroviral therapy 21 784 95%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc
2534
Estimated MDR/RR-TB cases among 1 300
notified pulmonary TB cases (9101 600) 1524
Estimated % of TB cases with 014
MDR/RR-TB 1.3% (0.681.9) 9.4% (8.710)
% notified tested for 10 000 5000 0 5000 10 000 15 000
rifampicin resistance 26% 42% 20 884
MDR/RR-TB cases tested for resistance to second-line drugs 204 Females Males

Laboratory-confirmed cases MDR/RR-TB: 326, XDR-TB: 9

Patients started on treatmentd MDR/RR-TB: 326, XDR-TB: 7 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 87% 80 310 60
Previously treated cases, excluding relapse, registered in 2015 83% 224
HIV-positive TB cases registered in 2015 82% 25 892 40
MDR/RR-TB cases started on second-line treatment in 2014 72% 251
XDR-TB cases started on second-line treatment in 2014 100% 1 20

TB preventive treatment, 20 16 0

% of HIV-positive people (newly enrolled in care) on preventive treatment 11% 2000 2003 2006 2009 2012 2015

% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment 14% (1315) HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17
National TB budget (US$ millions) 62
60
Funding source: 18% domestic, 41% international, 41% unfunded
Total budget (US$ millions)

40

20

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

174 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

20 50
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

10 30
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

10 50
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

50 10
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

200 3000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

60 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

70
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 175
 Mozambique POPULATION 2016 29 MILLION
Estimates of TB burden,a 20 16 150

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 22 (1333) 75 (44115)
Mortality (HIV+TB only) 33 (2048) 114 (70167) 100
Incidence (includes HIV+TB) 159 (103227) 551 (356787)
Incidence (HIV+TB only) 72 (46104) 249 (158360)
Incidence (MDR/RR-TB)b 7.6 (4.511) 26 (1637) 50

Estimated TB incidence by age and sex (thousands),a 20 16

014 years > 14 years Total 0
Females 10 (6.214) 50 (3070) 60 (3784) 2000 2004 2008 2012 2016
Males 12 (7.116) 87 (53121) 98 (60137)
Total 22 (1330) 137 (83191) 159 (103227)

(Rate per 100 000 population per year)

800
TB case notifications, 20 16
Total cases notified 73 470
600
Total new and relapse 71 842

Incidence
% tested with rapid diagnostics at time of diagnosis
400
% with known HIV status 94%
% pulmonary 90%
% bacteriologically confirmed among pulmonary 45% 200

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 45% (3270) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs
Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.36 (0.190.54) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016

Number (%)
Patients with known HIV-status who are HIV-positive 30 673 44%
15
on antiretroviral therapy 28 964 94%

Drug-resistant TB care, 20 16
New cases Previously treated cases Total numberc
Estimated MDR/RR-TB cases among 3 400 014
notified pulmonary TB cases (2 1004 800)
Estimated % of TB cases with
MDR/RR-TB 3.7% (2.45) 20% (2.137)
% notified tested for 30 000 20 000 10 000 0 10 000 20 000 30 000 40 000
rifampicin resistance 48% 55% 35 880
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 868
Laboratory-confirmed cases MDR/RR-TB: 911, XDR-TB: 25
Patients started on treatmentd MDR/RR-TB: 897, XDR-TB: 25 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 88% 58 344 60
Previously treated cases, excluding relapse, registered in 2015 88% 3 215
HIV-positive TB cases registered in 2015 86% 32 937 40

MDR/RR-TB cases started on second-line treatment in 2014 50% 439

XDR-TB cases started on second-line treatment in 2014 20

TB preventive treatment, 20 16 0
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment 52%
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment 100% (91100) HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17
National TB budget (US$ millions) 32 30
Funding source: 4% domestic, 96% international, 0% unfunded
Total budget (US$ millions)

20

10

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

176 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

20 100
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

10 10
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

10 50
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

50 5
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

100 1500
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

20 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

100
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 177
 Myanmar POPULATION 2016 53 MILLION
Estimates of TB burden,a 20 16 250

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)
200

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 25 (1635) 47 (3066)
Mortality (HIV+TB only) 4.9 (3.56.6) 9.3 (6.712)
150
Incidence (includes HIV+TB) 191 (141249) 361 (266471)
Incidence (HIV+TB only) 18 (1324) 34 (2545)
100
Incidence (MDR/RR-TB)b 13 (8.818) 25 (1734)

50
Estimated TB incidence by age and sex (thousands),a 20 16
014 years > 14 years Total 0
Females 11 (7.714) 58 (4174) 68 (4988)
2000 2004 2008 2012 2016
Males 12 (8.716) 111 (79142) 123 (88157)
Total 23 (1629) 168 (120216) 191 (141249)

(Rate per 100 000 population per year)

TB case notifications, 20 16 600

Total cases notified 139 625

Total new and relapse 137 551
400

Incidence
% tested with rapid diagnostics at time of diagnosis
% with known HIV status 83%
% pulmonary 89% 200
% bacteriologically confirmed among pulmonary 41%

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 72% (5598) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs, 2016 60% Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.16 (0.10.23) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016
65
Number (%)
Patients with known HIV-status who are HIV-positive 10 952 9% 5564
on antiretroviral therapy 6 351 58%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534

Estimated MDR/RR-TB cases among 9 000
1524
notified pulmonary TB cases (6 10012 000)
Estimated % of TB cases with 014
MDR/RR-TB 5.1% (3.27) 27% (1044)
% notified tested for 15 000 10 000 5000 0 5000 10 000 15 000 20 000
rifampicin resistance 15% 63% 27 699
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs
Laboratory-confirmed cases MDR/RR-TB: 3 213, XDR-TB:
Patients started on treatmentd MDR/RR-TB: 2 537, XDR-TB: 5 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 87% 136 201 60

Previously treated cases, excluding relapse, registered in 2015 75% 2 222

40
HIV-positive TB cases registered in 2015 72% 11 181
MDR/RR-TB cases started on second-line treatment in 2014 80% 1 497
20
XDR-TB cases started on second-line treatment in 2014

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment 3%
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment 1.9% (1.82.1) HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 80
National TB budget (US$ millions) 78
Funding source: 16% domestic, 84% international, <1% unfunded
Total budget (US$ millions)

60

40

20
Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding.
a
Ranges represent uncertainty intervals. Estimates of TB incidence and mortality for Myanmar will be 0
reviewed following completion of the 2017/2018 national TB prevalence survey. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

178 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

1
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population)
2000 2015 2000 2015

10 5
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

3 100
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

100 10
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

150 6000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

100
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0
2000 2015 2000 2015

50
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 179
 Nigeria POPULATION 2016 186 MILLION
Estimates of TB burden,a 20 16 100

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)
80

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 115 (67176) 62 (3695)
Mortality (HIV+TB only) 39 (2358) 21 (1231)
60
Incidence (includes HIV+TB) 407 (266579) 219 (143311)
Incidence (HIV+TB only) 63 (4093) 34 (2150)
40
Incidence (MDR/RR-TB)b 20 (1229) 11 (6.415)

20
Estimated TB incidence by age and sex (thousands),a 20 16
014 years > 14 years Total 0
Females 26 (1636) 114 (70158) 140 (86194) 2000 2004 2008 2012 2016
Males 30 (1841) 237 (146329) 267 (164370)
Total 56 (3477) 352 (216487) 407 (266579)
400

(Rate per 100 000 population per year)

TB case notifications, 20 16
Total cases notified 100 433 300
Total new and relapse 97 279

Incidence
% tested with rapid diagnostics at time of diagnosis 200
% with known HIV status 94%
% pulmonary 95%
% bacteriologically confirmed among pulmonary 73% 100

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 24% (1737) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs
Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.39 (0.20.6) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016

Number (%) 65

Patients with known HIV-status who are HIV-positive 14 794 16% 5564
on antiretroviral therapy 11 934 81%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534
Estimated MDR/RR-TB cases among 5 200
notified pulmonary TB cases (4 1006 200) 1524

Estimated % of TB cases with 014

MDR/RR-TB 4.3% (3.25.4) 25% (1931)
% notified tested for 15 000 10 000 5000 0 5000 10 000 15 000 20 000
rifampicin resistance 38% 71% 39 819
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs
Laboratory-confirmed cases MDR/RR-TB: 1 686, XDR-TB: 5
Patients started on treatmentd MDR/RR-TB: 1 251, XDR-TB: 4 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 84% 87 211 60

Previously treated cases, excluding relapse, registered in 2015 84% 3 373

40
HIV-positive TB cases registered in 2015 76% 14 846
MDR/RR-TB cases started on second-line treatment in 2014 74% 423
20
XDR-TB cases started on second-line treatment in 2014 0% 2

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment 29%
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment 18% (1720) HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 400
National TB budget (US$ millions) 336
Funding source: 9% domestic, 27% international, 64% unfunded
Total budget (US$ millions)

300

200

100

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

180 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

5 100
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

10 10
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

10 10
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

20 20
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

500 6000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

100 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

100
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 181
 Pakistan POPULATION 2016 193 MILLION
Estimates of TB burden,a 20 16 50

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)
40

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 44 (3455) 23 (1829)
Mortality (HIV+TB only) 2.1 (0.983.6) 1.1 (0.511.9)
30
Incidence (includes HIV+TB) 518 (335741) 268 (174383)
Incidence (HIV+TB only) 6.9 (3.212) 3.5 (1.66.2)
20
Incidence (MDR/RR-TB)b 27 (1737) 14 (8.819)

10
Estimated TB incidence by age and sex (thousands),a 20 16
014 years > 14 years Total 0
Females 24 (1534) 207 (126288) 231 (141322) 2000 2004 2008 2012 2016
Males 27 (1738) 260 (158362) 287 (175400)
Total 51 (3171) 467 (284650) 518 (335741)

(Rate per 100 000 population per year)

400
TB case notifications, 20 16
Total cases notified 366 061
300
Total new and relapse 356 390

Incidence
% tested with rapid diagnostics at time of diagnosis
200
% with known HIV status 4%
% pulmonary 80%
% bacteriologically confirmed among pulmonary 48% 100

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 69% (48110) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.09 (0.060.14) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016
65
Number (%)
Patients with known HIV-status who are HIV-positive 71 <1% 5564
on antiretroviral therapy 68 96%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534

Estimated MDR/RR-TB cases among 15 000
1524
notified pulmonary TB cases (12 00018 000)
Estimated % of TB cases with 014
MDR/RR-TB 4.2% (3.25.3) 16% (1517)
% notified tested for 50 000 40 000 30 000 20 000 10 000 0 10 000 20 000 30 000 40 000
rifampicin resistance 3% 50% 35 984
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 2 364
Laboratory-confirmed cases MDR/RR-TB: 3 331, XDR-TB: 126
Patients started on treatmentd MDR/RR-TB: 2 881, XDR-TB: 76 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 93% 323 267 60

Previously treated cases, excluding relapse, registered in 2015 83% 8 091

40
HIV-positive TB cases registered in 2015
MDR/RR-TB cases started on second-line treatment in 2014 65% 2 565
20
XDR-TB cases started on second-line treatment in 2014 42% 78

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 120
National TB budget (US$ millions) 108
100
Funding source: 7% domestic, 65% international, 28% unfunded
Total budget (US$ millions)

80

60

40

20
Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

182 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

1 40
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

20 20
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

1 40
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

50 50
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

200 5000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

100 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

50
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 183
 Philippines POPULATION 2016 103 MILLION
Estimates of TB burden,a 20 16 50

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)
40

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 22 (2222) 21 (2122)
Mortality (HIV+TB only) 0.3 (02.6) 0.29 (02.5)
30
Incidence (includes HIV+TB) 573 (321895) 554 (311866)
Incidence (HIV+TB only) 6 (2.511) 5.9 (2.411)
20
Incidence (MDR/RR-TB)b 30 (2140) 30 (2039)

10
Estimated TB incidence by age and sex (thousands),a 20 16
014 years > 14 years Total 0
Females 33 (1650) 136 (68205) 169 (84255) 2000 2004 2008 2012 2016
Males 37 (1856) 366 (182550) 403 (200606)
Total 70 (35106) 502 (249755) 573 (321895)
1000

(Rate per 100 000 population per year)

TB case notifications, 20 16
800
Total cases notified 345 144
Total new and relapse 332 941 600

Incidence
% tested with rapid diagnostics at time of diagnosis 13%
% with known HIV status 19% 400
% pulmonary 98%
% bacteriologically confirmed among pulmonary 37% 200

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 58% (37100) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs, 2017 35%
Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.04 (0.020.06) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016

Number (%) 65

Patients with known HIV-status who are HIV-positive 1 009 2% 5564

on antiretroviral therapy 820 81%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534
Estimated MDR/RR-TB cases among 20 000
notified pulmonary TB cases (15 00024 000) 1524

Estimated % of TB cases with 014

MDR/RR-TB 2.6% (1.83.3) 29% (2038)
% notified tested for 30 000 20 000 10 000 0 10 000 20 000 30 000 40 000
rifampicin resistance 7% 67% 50 752
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 432
Laboratory-confirmed cases MDR/RR-TB: 5 233, XDR-TB: 5
Patients started on treatmentd MDR/RR-TB: 5 253, XDR-TB: 5 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 91% 263 481 60

Previously treated cases, excluding relapse, registered in 2015 82% 7 925

40
HIV-positive TB cases registered in 2015 65% 277
MDR/RR-TB cases started on second-line treatment in 2014 46% 2 490
20
XDR-TB cases started on second-line treatment in 2014 0% 7

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment 49%
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment 5% (4.65.5) HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 150
National TB budget (US$ millions)e 104
Funding source: 19% domestic, 53% international, 28% unfunded
Total budget (US$ millions)

100

50

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding.
a
Ranges represent uncertainty intervals. 0
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin. 2013 2014 2015 2016 2017
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed.
e
The national budget does not include the budgets of local government units. Funded domestically Funded internationally Unfunded

184 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

1 20
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

10 50
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

10 30
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

70 50
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

500 8000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

100 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

50
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 185
 Russian Federation POPULATION 2016a 144 MILLION
Estimates of TB burden,b 20 16 30

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 12 (1112) 8.2 (7.88.6)
Mortality (HIV+TB only) 1.7 (0.852.7) 1.2 (0.591.9) 20
Incidence (includes HIV+TB) 94 (61135) 66 (4294)
Incidence (HIV+TB only) 18 (1226) 13 (8.118)
Incidence (MDR/RR-TB)c 63 (5274) 44 (3651) 10

Estimated TB incidence by age and sex (thousands),b 20 16

014 years > 14 years Total 0
Females 4.7 (2.96.6) 25 (1535) 30 (1842) 2000 2004 2008 2012 2016
Males 5.4 (3.37.5) 59 (3682) 65 (3990)
Total 10 (6.114) 84 (51118) 94 (61135)
150

(Rate per 100 000 population per year)

TB case notifications, 20 16
Total cases notified 121 046
Total new and relapse 92 407 100

Incidence
% tested with rapid diagnostics at time of diagnosis 70%
% with known HIV status 87%
% pulmonary 91% 50
% bacteriologically confirmed among pulmonary 51%

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 98% (68150) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs
Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.15 (0.10.21) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016

Number (%) 65

Patients with known HIV-status who are HIV-positive 16 570 21% 5564
on antiretroviral therapy 10 549 64%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberd 2534
Estimated MDR/RR-TB cases among 47 000
notified pulmonary TB cases (46 00047 000) 1524

Estimated % of TB cases with 014

MDR/RR-TB 27% (2728) 65% (6566)
% notified tested for 10 000 5000 0 5000 10 000 15 000 20 000
rifampicin resistance 40% 63% 57 910
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs
Laboratory-confirmed cases MDR/RR-TB: 27 363, XDR-TB:
Patients started on treatmente MDR/RR-TB: 25 713, XDR-TB: 1 772 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 71% 80 424 60

Previously treated cases, excluding relapse, registered in 2015 50% 8 294

40
HIV-positive TB cases registered in 2015 51% 694
MDR/RR-TB cases started on second-line treatment in 2014 51% 20 089
20
XDR-TB cases started on second-line treatment in 2014 31% 2 209

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment 93%
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment 100% (100100) HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 2000
National TB budget (US$ millions) 1 175
Funding source: 100% domestic, 0% international, 0% unfunded
Total budget (US$ millions)

1500

1000

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation 500
with countries. Estimates are rounded and totals are computed prior to rounding.
a
UN Population Division estimates are lower than the population registered by the Federal State Statistics
Service of the Russian Federation. 0
b
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
c
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
d
Includes cases with unknown previous TB treatment history.
e
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

186 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

4
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
(% of population) 0
2000 2015 2000 2015

10 100
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

40
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0
! females ! males 2000 2015 2000 2015

80 100
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

2500 30 000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

50 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 187
 South Africa POPULATION 2016 56 MILLION
Estimates of TB burden,a 20 16 80

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 23 (1729) 41 (3152) 60
Mortality (HIV+TB only) 101 (67142) 181 (120254)
Incidence (includes HIV+TB) 438 (304595) 781 (5431 060)
40
Incidence (HIV+TB only) 258 (176355) 461 (315635)
Incidence (MDR/RR-TB)b 19 (1225) 34 (2245)
20
Estimated TB incidence by age and sex (thousands),a 20 16
014 years > 14 years Total 0
Females 27 (1836) 154 (103206) 182 (121242)
2000 2004 2008 2012 2016
Males 31 (2041) 226 (150301) 256 (171342)
Total 58 (3877) 380 (253507) 438 (304595)
1500

(Rate per 100 000 population per year)

TB case notifications, 20 16
Total cases notified 244 053
1000
Total new and relapse 237 045

Incidence
% tested with rapid diagnostics at time of diagnosis 69%
% with known HIV status 96%
% pulmonary 90% 500

% bacteriologically confirmed among pulmonary 67%

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 54% (4078) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs
Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.29 (0.170.43) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016
65
Number (%)
Patients with known HIV-status who are HIV-positive 135 169 59% 5564
on antiretroviral therapy 119 213 88%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534

Estimated MDR/RR-TB cases among 8 200
1524
notified pulmonary TB cases (6 40010 000)
Estimated % of TB cases with 014
MDR/RR-TB 3.4% (2.54.3) 7.1% (4.89.5)
% notified tested for 30 000 20 000 10 000 0 10 000 20 000 30 000 40 000
rifampicin resistance 215 696
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 11 903
Laboratory-confirmed cases MDR/RR-TB: 19 073, XDR-TB: 967
100
Patients started on treatmentd MDR/RR-TB: 11 192, XDR-TB: 628

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
60
New and relapse cases registered in 2015 81% 291 793
Previously treated cases, excluding relapse, registered in 2015 63% 5 441
40
HIV-positive TB cases registered in 2015 80% 167 335
MDR/RR-TB cases started on second-line treatment in 2014 54% 11 111 20
XDR-TB cases started on second-line treatment in 2014 27% 610
0
TB preventive treatment, 20 16 2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment 51%
New and relapse Retreatment, excluding relapse
% of children (aged < 5) household contacts of bacteriologically-confirmed HIV-positive MDR/RR-TB XDR-TB
TB cases on preventive treatment

TB financing, 20 17 500

National TB budget (US$ millions) 244

400
Total budget (US$ millions)

Funding source: 90% domestic, 10% international, 0% unfunded

300

200

100

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
0
with countries. Estimates are rounded and totals are computed prior to rounding.
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history. Funded domestically Funded internationally Unfunded
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed.

188 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

30 50
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

20 100
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

10 10
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

50 100
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

2000 20 000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

20 100
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

50
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 189
 Thailand POPULATION 2016 69 MILLION
Estimates of TB burden,a 20 16 60

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 8.6 (7.210) 13 (1015)
Mortality (HIV+TB only) 3.9 (2.35.9) 5.7 (3.48.6) 40
Incidence (includes HIV+TB) 119 (70180) 172 (102261)
Incidence (HIV+TB only) 10 (6.116) 15 (8.823)
Incidence (MDR/RR-TB)b 4.7 (36.3) 6.8 (4.49.2) 20

Estimated TB incidence by age and sex (thousands),a 20 16

014 years > 14 years Total 0
Females 4.2 (2.36.1) 36 (1952) 40 (2158)
2000 2004 2008 2012 2016
Males 4.7 (2.56.9) 74 (40108) 79 (42115)
Total 8.9 (4.813) 110 (59161) 119 (70180)
500

(Rate per 100 000 population per year)

TB case notifications, 20 16
400
Total cases notified 72 014
Total new and relapse 68 040
300

Incidence
% tested with rapid diagnostics at time of diagnosis 1%
% with known HIV status 81%
200
% pulmonary 84%
% bacteriologically confirmed among pulmonary 60%
100

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 57% (3897) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs
Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.11 (0.060.17) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016

Number (%) 65
Patients with known HIV-status who are HIV-positive 4 764 8%
5564
on antiretroviral therapy 2 833 59%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc
2534
Estimated MDR/RR-TB cases among 2 700
notified pulmonary TB cases (2 1003 300) 1524
Estimated % of TB cases with 014
MDR/RR-TB 2.2% (1.52.9) 24% (1632)
% notified tested for 6000 4000 2000 0 2000 4000 6000 8000 10 000
rifampicin resistance 8% 18% 6 889
MDR/RR-TB cases tested for resistance to second-line drugs 499 Females Males
Laboratory-confirmed cases MDR/RR-TB: 955, XDR-TB: 13
Patients started on treatmentd MDR/RR-TB: 952, XDR-TB: 8 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 81% 56 111 60
Previously treated cases, excluding relapse, registered in 2015 70% 4 350
HIV-positive TB cases registered in 2015 71% 5 524 40
MDR/RR-TB cases started on second-line treatment in 2014 58% 414
XDR-TB cases started on second-line treatment in 2014 20

TB preventive treatment, 20 16 0

% of HIV-positive people (newly enrolled in care) on preventive treatment 2000 2003 2006 2009 2012 2015

% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17
National TB budget (US$ millions) 20
30
Funding source: 77% domestic, 18% international, 6% unfunded
Total budget (US$ millions)

20

10

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

190 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

5 3
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

10 100
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

10 20
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

50 100
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

1000 20 000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

50 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

30
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 191
 United Republic of Tanzania POPULATION 2016 56 MILLION
Estimates of TB burden,a 20 16 150

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 28 (1350) 51 (2390)
Mortality (HIV+TB only) 27 (1246) 48 (2283) 100
Incidence (includes HIV+TB) 160 (75275) 287 (136495)
Incidence (HIV+TB only) 54 (3578) 98 (63140)
Incidence (MDR/RR-TB)b 2.6 (0.634.6) 4.7 (1.18.3) 50

Estimated TB incidence by age and sex (thousands),a 20 16

014 years > 14 years Total 0
Females 4.2 (1.56.8) 48 (1878) 52 (1985) 2000 2004 2008 2012 2016
Males 4.8 (1.87.8) 103 (38167) 107 (40175)
Total 9 (3.315) 151 (56246) 160 (75275)

(Rate per 100 000 population per year)

800
TB case notifications, 20 16
Total cases notified 65 908
600
Total new and relapse 64 609

Incidence
% tested with rapid diagnostics at time of diagnosis 8%
400
% with known HIV status 97%
% pulmonary 79%
% bacteriologically confirmed among pulmonary 54% 200

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 40% (2486) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.38 (0.140.66) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016
65
Number (%)
Patients with known HIV-status who are HIV-positive 21 720 34% 5564
on antiretroviral therapy 19 814 91%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534

Estimated MDR/RR-TB cases among 830
1524
notified pulmonary TB cases (4201 200)
Estimated % of TB cases with 014
MDR/RR-TB 1.3% (0.472.1) 6.2% (5.17.4)
% notified tested for 6000 4000 2000 0 2000 4000 6000 8000 10 000
rifampicin resistance 13% 58% 9 949
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 97
Laboratory-confirmed cases MDR/RR-TB: 196, XDR-TB: 0
Patients started on treatmentd MDR/RR-TB: 158, XDR-TB: 0 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 90% 60 895 60

Previously treated cases, excluding relapse, registered in 2015 80% 1 292

40
HIV-positive TB cases registered in 2015 83% 22 675
MDR/RR-TB cases started on second-line treatment in 2014 76% 143
20
XDR-TB cases started on second-line treatment in 2014 0% 1

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment 9%
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment 31% (2834) HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 80
National TB budget (US$ millions) 70
Funding source: 3% domestic, 39% international, 58% unfunded
Total budget (US$ millions)

60

40

20

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

192 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

10 100
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

10 30
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

10 50
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

50 5
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

200 3000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

50 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

100
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 193
 Viet Nam POPULATION 2016 95 MILLION
Estimates of TB burden,a 20 16 60

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 13 (8.418) 14 (8.919)
Mortality (HIV+TB only) 0.85 (0.631.1) 0.9 (0.661.2) 40
Incidence (includes HIV+TB) 126 (103151) 133 (109159)
Incidence (HIV+TB only) 4.2 (3.45.1) 4.4 (3.65.4)
Incidence (MDR/RR-TB)b 8.2 (6.110) 8.7 (6.511) 20

Estimated TB incidence by age and sex (thousands),a 20 16

014 years > 14 years Total 0
Females 7.3 (5.98.7) 26 (2130) 33 (2739) 2000 2004 2008 2012 2016
Males 8.2 (6.79.8) 85 (69101) 93 (75110)
Total 15 (1318) 110 (89131) 126 (103151)
300

(Rate per 100 000 population per year)

TB case notifications, 20 16
Total cases notified 106 527
Total new and relapse 102 097 200

Incidence
% tested with rapid diagnostics at time of diagnosis 6%
% with known HIV status 79%
% pulmonary 81% 100
% bacteriologically confirmed among pulmonary 69%

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 81% (6899) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs, 2016 63%
Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.11 (0.070.16) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016

Number (%) 65

Patients with known HIV-status who are HIV-positive 2 669 3% 5564

on antiretroviral therapy 2 419 91%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534
Estimated MDR/RR-TB cases among 5 500
notified pulmonary TB cases (4 4006 600) 1524

Estimated % of TB cases with 014

MDR/RR-TB 4.1% (2.65.5) 26% (2527)
% notified tested for 10 000 5000 0 5000 10 000 15 000 20 000
rifampicin resistance 19% 95% 29 299
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 556
Laboratory-confirmed cases MDR/RR-TB: 3 084, XDR-TB: 40
Patients started on treatmentd MDR/RR-TB: 2 450, XDR-TB: 28 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 92% 97 466 60

Previously treated cases, excluding relapse, registered in 2015 77% 1 896

40
HIV-positive TB cases registered in 2015 78% 3 428
MDR/RR-TB cases started on second-line treatment in 2014 75% 1 528
20
XDR-TB cases started on second-line treatment in 2014 0

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment 26%
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment 19% (1821) HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 80
National TB budget (US$ millions) 70
Funding source: 8% domestic, 28% international, 63% unfunded
Total budget (US$ millions)

60

40

20

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

194 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

1 50
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

10 100
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

10 40
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

100 60
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

500 7000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

100 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

50
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 195
 Cambodia POPULATION 2016 16 MILLION
Estimates of TB burden,a 20 16 60

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 3.2 (2.14.4) 20 (1428)
Mortality (HIV+TB only) 0.45 (0.290.66) 2.9 (1.84.2) 40
Incidence (includes HIV+TB) 54 (3578) 345 (223493)
Incidence (HIV+TB only) 1.3 (0.851.9) 8.5 (5.412)
Incidence (MDR/RR-TB)b 1.2 (0.531.9) 7.7 (3.412) 20

Estimated TB incidence by age and sex (thousands),a 20 16

014 years > 14 years Total 0
Females 3.2 (1.94.4) 19 (1227) 23 (1431) 2000 2004 2008 2012 2016
Males 3.6 (2.25) 28 (1739) 32 (1944)
Total 6.7 (4.19.4) 48 (2966) 54 (3578)
1000

(Rate per 100 000 population per year)

TB case notifications, 20 16
800
Total cases notified 33 736
Total new and relapse 33 453 600

Incidence
% tested with rapid diagnostics at time of diagnosis
% with known HIV status 86% 400
% pulmonary 67%
% bacteriologically confirmed among pulmonary 50% 200

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 62% (4395) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs
Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.07 (0.040.11) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016

Number (%) 65

Patients with known HIV-status who are HIV-positive 721 3% 5564

on antiretroviral therapy 708 98%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534
Estimated MDR/RR-TB cases among 550
notified pulmonary TB cases (260840) 1524

Estimated % of TB cases with 014

MDR/RR-TB 1.8% (0.772.8) 11% (023)
% notified tested for 4000 3000 2000 1000 0 1000 2000 3000 4000
rifampicin resistance 1% 70% 1 542
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 0
Laboratory-confirmed cases MDR/RR-TB: 101, XDR-TB: 1
Patients started on treatmentd MDR/RR-TB: 101, XDR-TB: 1 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 94% 35 167 60

Previously treated cases, excluding relapse, registered in 2015 88% 226

40
HIV-positive TB cases registered in 2015
MDR/RR-TB cases started on second-line treatment in 2014 76% 110
20
XDR-TB cases started on second-line treatment in 2014 0

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment 20%
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment 36% (3339) HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 40
National TB budget (US$ millions) 37
Funding source: 9% domestic, 39% international, 52% unfunded
Total budget (US$ millions)

30

20

10

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

196 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

10 25
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

10 5
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

20 50
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

100 20
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

300 5000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

100 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

100
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 197
 Central African Republic POPULATION 2016 4.6 MILLION
Estimates of TB burden,a 20 16 300

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 2.7 (1.54.2) 59 (3392)
Mortality (HIV+TB only) 2.5 (1.34) 54 (2987) 200
Incidence (includes HIV+TB) 19 (1227) 407 (263581)
Incidence (HIV+TB only) 6.2 (3.39.9) 134 (73215)
Incidence (MDR/RR-TB)b 0.18 (00.41) 4.0 (08.9) 100

Estimated TB incidence by age and sex (thousands),a 20 16

014 years > 14 years Total 0
Females 1.2 (0.731.7) 5.9 (3.68.2) 7.1 (4.39.9) 2000 2004 2008 2012 2016
Males 1.4 (0.831.9) 10 (6.214) 12 (716)
Total 2.6 (1.63.6) 16 (9.822) 19 (1227)
1600

(Rate per 100 000 population per year)

TB case notifications, 20 16
Total cases notified 10 229 1200
Total new and relapse 9 968

Incidence
% tested with rapid diagnostics at time of diagnosis 800
% with known HIV status 66%
% pulmonary 81%
% bacteriologically confirmed among pulmonary 64% 400

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 53% (3782) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs
Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.29 (0.150.45) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016

Number (%) 65

Patients with known HIV-status who are HIV-positive 2 047 30% 5564
on antiretroviral therapy 1 580 77%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534
Estimated MDR/RR-TB cases among 110
notified pulmonary TB cases (12210) 1524

Estimated % of TB cases with 014

MDR/RR-TB 0.4% (01.6) 13% (8.917)
% notified tested for 1500 1000 500 0 500 1000 1500
rifampicin resistance 0% 34% 206
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 0
Laboratory-confirmed cases MDR/RR-TB: 57, XDR-TB: 0
Patients started on treatmentd MDR/RR-TB: 51, XDR-TB: 0 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 78% 4 957 60

Previously treated cases, excluding relapse, registered in 2015 84% 521

40
HIV-positive TB cases registered in 2015 75% 1 877
MDR/RR-TB cases started on second-line treatment in 2014 76% 21
20
XDR-TB cases started on second-line treatment in 2014 0

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 5
National TB budget (US$ millions) 1.6
Funding source: 18% domestic, 65% international, 17% unfunded 4
Total budget (US$ millions)

1
Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

198 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

10 100
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
(% of population) 0
0
2000 2015 2000 2015

10 5
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

10 60
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

5
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population) 0
2000 2015 2000 2015

100 1000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

100 100
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

100
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 199
 Congo POPULATION 2016 5.1 MILLION
Estimates of TB burden,a 20 16 120

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 3.1 (1.74.8) 60 (3493)
Mortality (HIV+TB only) 2.1 (1.13.4) 41 (2166) 80
Incidence (includes HIV+TB) 19 (1228) 378 (240547)
Incidence (HIV+TB only) 5.1 (2.68.4) 100 (52163)
Incidence (MDR/RR-TB)b 0.64 (0.390.9) 13 (7.518) 40

Estimated TB incidence by age and sex (thousands),a 20 16

014 years > 14 years Total 0
Females 1.3 (0.751.8) 6.1 (3.68.6) 7.3 (4.310) 2000 2004 2008 2012 2016
Males 1.4 (0.852) 11 (6.315) 12 (7.117)
Total 2.7 (1.63.8) 17 (9.923) 19 (1228)

(Rate per 100 000 population per year)

TB case notifications, 20 16 600

Total cases notified 10 656

Total new and relapse 10 424
400

Incidence
% tested with rapid diagnostics at time of diagnosis 3%
% with known HIV status 30%
% pulmonary 74% 200
% bacteriologically confirmed among pulmonary 45%

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 54% (3785) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.28 (0.140.43) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016
65
Number (%)
Patients with known HIV-status who are HIV-positive 516 16% 5564
on antiretroviral therapy 224 43%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534

Estimated MDR/RR-TB cases among 270
1524
notified pulmonary TB cases (220310)
Estimated % of TB cases with 014
MDR/RR-TB 2.8% (2.13.4) 13% (8.917)
% notified tested for 1000 500 0 500 1000 1500
rifampicin resistance 0% 74% 336
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs
Laboratory-confirmed cases MDR/RR-TB: 29, XDR-TB:
Patients started on treatmentd MDR/RR-TB: 0, XDR-TB: 0 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 71% 9 807 60

Previously treated cases, excluding relapse, registered in 2015 45% 196

40
HIV-positive TB cases registered in 2015 20% 503
MDR/RR-TB cases started on second-line treatment in 2014 0
20
XDR-TB cases started on second-line treatment in 2014 0

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 4
National TB budget (US$ millions) 2.2
Funding source: 88% domestic, 12% international, 0% unfunded
Total budget (US$ millions)

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

20 0 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

60
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
(% of population) 0
2000 2015 2000 2015

10 10
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

10 50
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

50 20
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

500 8000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

60 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

60
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 20 1
 Lesotho POPULATION 2016 2.2 MILLION
Estimates of TB burden,a 20 16 150

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 1.1 (0.561.8) 49 (2680)
Mortality (HIV+TB only) 5.2 (3.37.7) 238 (148350) 100
Incidence (includes HIV+TB) 16 (1023) 724 (4681 030)
Incidence (HIV+TB only) 12 (7.317) 525 (332760)
Incidence (MDR/RR-TB)b 1.1 (0.711.4) 49 (3266) 50

Estimated TB incidence by age and sex (thousands),a 20 16

014 years > 14 years Total 0
Females 1.1 (0.671.5) 5 (37) 6.1 (3.78.5) 2000 2004 2008 2012 2016
Males 1.2 (0.751.7) 8.6 (5.212) 9.9 (614)
Total 2.3 (1.43.3) 14 (8.319) 16 (1023)
2000

(Rate per 100 000 population per year)

TB case notifications, 20 16
Total cases notified 7 513 1500
Total new and relapse 7 291

Incidence
% tested with rapid diagnostics at time of diagnosis
1000
% with known HIV status 91%
% pulmonary 89%
% bacteriologically confirmed among pulmonary 56% 500

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 46% (3271) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs
Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.41 (0.210.63) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016

Number (%) 65
Patients with known HIV-status who are HIV-positive 4 949 73% 5564
on antiretroviral therapy 4 243 86%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc
2534
Estimated MDR/RR-TB cases among 410
notified pulmonary TB cases (330490) 1524
Estimated % of TB cases with 014
MDR/RR-TB 4.8% (3.75.9) 14% (9.218)
% notified tested for 1000 500 0 500 1000 1500
rifampicin resistance
MDR/RR-TB cases tested for resistance to second-line drugs Females Males

Laboratory-confirmed cases MDR/RR-TB: , XDR-TB:

Patients started on treatmentd MDR/RR-TB: 238, XDR-TB: 0 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 74% 7 557 60
Previously treated cases, excluding relapse, registered in 2015 64% 299
HIV-positive TB cases registered in 2015 77% 5 988 40
MDR/RR-TB cases started on second-line treatment in 2014 64% 152
XDR-TB cases started on second-line treatment in 2014 20

TB preventive treatment, 20 16 0
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17
National TB budget (US$ millions) 4.7 6
Funding source: 17% domestic, 67% international, 16% unfunded
Total budget (US$ millions)

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

20 2 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

30 100
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

10 60
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

10 20
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

70 50
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

300 3000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

50 60
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

60
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 20 3
 Liberia POPULATION 2016 4.6 MILLION
Estimates of TB burden,a 20 16 150

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 2.8 (1.64.2) 60 (3591)
Mortality (HIV+TB only) 0.96 (0.61.4) 21 (1330) 100
Incidence (includes HIV+TB) 14 (9.220) 308 (199440)
Incidence (HIV+TB only) 2.2 (1.43.2) 48 (3170)
Incidence (MDR/RR-TB)b 0.43 (0.0460.82) 9.4 (118) 50

Estimated TB incidence by age and sex (thousands),a 20 16

014 years > 14 years Total 0
Females 0.77 (0.471.1) 4.4 (2.76.1) 5.2 (3.17.2) 2000 2004 2008 2012 2016
Males 0.87 (0.531.2) 8.2 (511) 9 (5.513)
Total 1.6 (0.992.3) 13 (7.718) 14 (9.220)
500

(Rate per 100 000 population per year)

TB case notifications, 20 16
400
Total cases notified 7 180
Total new and relapse 7 105
300

Incidence
% tested with rapid diagnostics at time of diagnosis
% with known HIV status 74%
200
% pulmonary 69%
% bacteriologically confirmed among pulmonary 63% 100

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 50% (3577) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs
Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.27 (0.140.42) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016

Number (%) 65
Patients with known HIV-status who are HIV-positive 829 16% 5564
on antiretroviral therapy 390 47%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc
2534
Estimated MDR/RR-TB cases among 160
notified pulmonary TB cases (36290) 1524
Estimated % of TB cases with 014
MDR/RR-TB 2.6% (0.15.1) 18% (0.136)
% notified tested for 1500 1000 500 0 500 1000 1500 2000 2500 3000
rifampicin resistance 24% 100% 1 876
MDR/RR-TB cases tested for resistance to second-line drugs 0 Females Males

Laboratory-confirmed cases MDR/RR-TB: 92, XDR-TB: 0

Patients started on treatmentd MDR/RR-TB: 75, XDR-TB: 0 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 77% 6 147 60
Previously treated cases, excluding relapse, registered in 2015 65% 43
HIV-positive TB cases registered in 2015 40
MDR/RR-TB cases started on second-line treatment in 2014 0
XDR-TB cases started on second-line treatment in 2014 0 20

TB preventive treatment, 20 16 0
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment 9%
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment 4.4% (44.8) HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17
National TB budget (US$ millions) 1.7 12

Funding source: 24% domestic, 76% international, 0% unfunded 10

Total budget (US$ millions)

2
Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

20 4 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

5 100
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0 (% of population) 0
2000 2015 2000 2015

10 100
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

10 50
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

40 5
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

100 1000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

50 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
0 0
health) 2000 2015 2000 2015

100
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 20 5
 Namibia POPULATION 2016 2.5 MILLION
Estimates of TB burden,a 20 16 80

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 0.75 (0.481.1) 30 (2044) 60
Mortality (HIV+TB only) 0.87 (0.611.2) 35 (2548)
Incidence (includes HIV+TB) 11 (8.514) 446 (342565)
40
Incidence (HIV+TB only) 4.2 (2.76) 171 (110244)
Incidence (MDR/RR-TB)b 0.96 (0.741.2) 39 (3047)
20
Estimated TB incidence by age and sex (thousands),a 20 16
014 years > 14 years Total 0
Females 0.87 (0.661.1) 3.8 (2.84.7) 4.7 (3.55.8) 2000 2004 2008 2012 2016
Males 0.99 (0.741.2) 5.4 (4.16.8) 6.4 (4.88)
Total 1.9 (1.42.3) 9.2 (6.912) 11 (8.514)
1250

(Rate per 100 000 population per year)

TB case notifications, 20 16
1000
Total cases notified 9 154
Total new and relapse 8 857 750

Incidence
% tested with rapid diagnostics at time of diagnosis
% with known HIV status 98% 500
% pulmonary 82%
% bacteriologically confirmed among pulmonary 80% 250

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 80% (63100) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.15 (0.10.2) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016
65
Number (%)
Patients with known HIV-status who are HIV-positive 3 410 38% 5564
on antiretroviral therapy 3 209 94%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534

Estimated MDR/RR-TB cases among 480
1524
notified pulmonary TB cases (410560)
Estimated % of TB cases with 014
MDR/RR-TB 5% (4.15.9) 12% (8.715)
% notified tested for 1500 1000 500 0 500 1000 1500
rifampicin resistance 3% 10% 387
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 54
Laboratory-confirmed cases MDR/RR-TB: 360, XDR-TB: 10
Patients started on treatmentd MDR/RR-TB: 362, XDR-TB: 10 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 83% 9 614 60

Previously treated cases, excluding relapse, registered in 2015 60% 330

40
HIV-positive TB cases registered in 2015 79% 3 796
MDR/RR-TB cases started on second-line treatment in 2014 70% 266
20
XDR-TB cases started on second-line treatment in 2014 33% 6

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment 26% (2428) HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 60
National TB budget (US$ millions) 56
Funding source: 30% domestic, 18% international, 52% unfunded
Total budget (US$ millions)

40

20

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

20 6 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

20 50
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

10 20
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

10 50
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

50 50
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

1000 10 000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

10 100
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

50
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 20 7
 Papua New Guinea POPULATION 2016 8.1 MILLION
Estimates of TB burden,a 20 16 200

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 3.6 (2.45) 44 (2962) 150
Mortality (HIV+TB only) 0.82 (0.451.3) 10 (5.516)
Incidence (includes HIV+TB) 35 (2842) 432 (352521)
100
Incidence (HIV+TB only) 3.6 (25.5) 44 (2568)
Incidence (MDR/RR-TB)b 1.9 (1.22.6) 23 (1532)
50
Estimated TB incidence by age and sex (thousands),a 20 16
014 years > 14 years Total 0
Females 1.8 (1.42.1) 11 (8.713) 13 (1015) 2000 2004 2008 2012 2016
Males 2 (1.62.4) 20 (1624) 22 (1827)
Total 3.8 (34.5) 31 (2537) 35 (2842)

(Rate per 100 000 population per year)

TB case notifications, 20 16 600

Total cases notified 29 751

Total new and relapse 27 576
400

Incidence
% tested with rapid diagnostics at time of diagnosis
% with known HIV status 33%
% pulmonary 57% 200
% bacteriologically confirmed among pulmonary 31%

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 79% (6597) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.13 (0.080.18) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016
65
Number (%)
Patients with known HIV-status who are HIV-positive 699 7% 5564
on antiretroviral therapy 642 92%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534

Estimated MDR/RR-TB cases among 1 200
1524
notified pulmonary TB cases (7901 500)
Estimated % of TB cases with 014
MDR/RR-TB 3.4% (1.75) 26% (1536)
% notified tested for 800 600 400 200 0 200 400 600 800
rifampicin resistance 7 785
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 210
Laboratory-confirmed cases MDR/RR-TB: 342, XDR-TB: 4
Patients started on treatmentd MDR/RR-TB: 302, XDR-TB: 2 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New cases registered in 2015 74% 4 110 60

Previously treated cases registered in 2015 63% 661

40
HIV-positive TB cases registered in 2015
MDR/RR-TB cases started on second-line treatment in 2014 52% 180
20
XDR-TB cases started on second-line treatment in 2014 40% 5

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed New cases Previously treated cases
TB cases on preventive treatment HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 25
National TB budget (US$ millions) 11
Funding source: 27% domestic, 73% international, 0% unfunded 20
Total budget (US$ millions)

15

10

5
Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

20 8 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

1 50
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

20 5
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

10
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0
! females ! males 2000 2015 2000 2015

50
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population) 0
2000 2015 2000 2015

200 3000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

20 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 20 9
 Sierra Leone POPULATION 2016 7.4 MILLION
Estimates of TB burden,a 20 16 150

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 3.4 (25.2) 47 (2870)
Mortality (HIV+TB only) 1 (0.661.5) 14 (920) 100
Incidence (includes HIV+TB) 22 (1432) 304 (195435)
Incidence (HIV+TB only) 3.1 (24.5) 42 (2761)
Incidence (MDR/RR-TB)b 0.72 (0.121.3) 9.7 (1.618) 50

Estimated TB incidence by age and sex (thousands),a 20 16

014 years > 14 years Total 0
Females 1.2 (0.741.7) 7.9 (4.811) 9.1 (5.513) 2000 2004 2008 2012 2016
Males 1.4 (0.841.9) 12 (7.217) 13 (8.119)
Total 2.6 (1.63.6) 20 (1228) 22 (1432)

(Rate per 100 000 population per year)

TB case notifications, 20 16 400
Total cases notified 14 114
Total new and relapse 14 114

Incidence
% tested with rapid diagnostics at time of diagnosis 0%
% with known HIV status 97% 200
% pulmonary 94%
% bacteriologically confirmed among pulmonary 85%

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 63% (4498) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.21 (0.110.33) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016
65
Number (%)
Patients with known HIV-status who are HIV-positive 1 914 14% 5564
on antiretroviral therapy 1 522 80%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534

Estimated MDR/RR-TB cases among 440
1524
notified pulmonary TB cases (99780)
Estimated % of TB cases with 014
MDR/RR-TB 2.6% (0.15.1) 18% (0.136)
% notified tested for 3000 2000 1000 0 1000 2000 3000 4000
rifampicin resistance 0% 10% 60
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 13
Laboratory-confirmed cases MDR/RR-TB: 13, XDR-TB: 0
Patients started on treatmentd MDR/RR-TB: 0, XDR-TB: 0 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New cases registered in 2015 88% 8 017 60

Previously treated cases registered in 2015 62% 227

40
HIV-positive TB cases registered in 2015
MDR/RR-TB cases started on second-line treatment in 2014
20
XDR-TB cases started on second-line treatment in 2014

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment 20%
% of children (aged < 5) household contacts of bacteriologically-confirmed New cases Previously treated cases
HIV-positive MDR/RR-TB XDR-TB
TB cases on preventive treatment

TB financing, 20 17 10
National TB budget (US$ millions) 6.9
Funding source: 3% domestic, 97% international, 0% unfunded 8
Total budget (US$ millions)

2
Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

210 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

5 100
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

10 50
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

10 50
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

100 5
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

300 2000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

100 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

100
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 211
 Zambia POPULATION 2016 17 MILLION
Estimates of TB burden,a 20 16 80

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 4.8 (2.87.3) 29 (1744) 60
Mortality (HIV+TB only) 12 (7.918) 74 (47107)
Incidence (includes HIV+TB) 62 (4089) 376 (244535)
40
Incidence (HIV+TB only) 36 (2352) 218 (140312)
Incidence (MDR/RR-TB)b 2.1 (1.42.9) 13 (8.417)
20
Estimated TB incidence by age and sex (thousands),a 20 16
014 years > 14 years Total 0
Females 3.6 (2.24.9) 20 (1228) 24 (1533) 2000 2004 2008 2012 2016
Males 4 (2.55.6) 34 (2148) 38 (2353)
Total 7.6 (4.611) 55 (3376) 62 (4089)
1250

(Rate per 100 000 population per year)

TB case notifications, 20 16
1000
Total cases notified 40 153
Total new and relapse 38 326
750

Incidence
% tested with rapid diagnostics at time of diagnosis
% with known HIV status 93% 500
% pulmonary 82%
% bacteriologically confirmed among pulmonary 50% 250

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 62% (4395) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs
Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.29 (0.160.43) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016

Number (%) 65

Patients with known HIV-status who are HIV-positive 21 655 58% 5564
on antiretroviral therapy 17 914 83%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534
Estimated MDR/RR-TB cases among 1 400
notified pulmonary TB cases (9101 900) 1524

Estimated % of TB cases with 014

MDR/RR-TB 1.1% (0.132.1) 18% (1225)
% notified tested for 6000 4000 2000 0 2000 4000 6000 8000
rifampicin resistance <1% 7% 526
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 0
Laboratory-confirmed cases MDR/RR-TB: 180, XDR-TB: 0
Patients started on treatmentd MDR/RR-TB: 136, XDR-TB: 0 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 85% 36 741 60

Previously treated cases, excluding relapse, registered in 2015 84% 4 847

40
HIV-positive TB cases registered in 2015 87% 20 967
MDR/RR-TB cases started on second-line treatment in 2014 51% 68
20
XDR-TB cases started on second-line treatment in 2014 0

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment 15%
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 40
National TB budget (US$ millions) 14
Funding source: 9% domestic, 52% international, 40% unfunded
Total budget (US$ millions)

30

20

10

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

212 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

20 100
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

10 2
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

10 100
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

50 20
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

200 5000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

50 100
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

100
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 213
 Zimbabwe POPULATION 2016 16 MILLION
Estimates of TB burden,a 20 16 50

(Rate per 100 000 population per year)

Number (thousands) Rate (per 100 000 population)
40

Mortality (excludes HIV + TB)

Mortality (excludes HIV+TB) 1.2 (0.711.7) 7.2 (4.411)
Mortality (HIV+TB only) 4.4 (36.1) 27 (1938)
30
Incidence (includes HIV+TB) 34 (2444) 208 (152273)
Incidence (HIV+TB only) 23 (1532) 139 (90199)
20
Incidence (MDR/RR-TB)b 1.9 (1.32.6) 12 (816)

10
Estimated TB incidence by age and sex (thousands),a 20 16
014 years > 14 years Total 0
Females 1.5 (11.9) 13 (916) 14 (1018) 2000 2004 2008 2012 2016
Males 1.7 (1.22.1) 18 (1323) 19 (1425)
Total 3.1 (2.24) 30 (2239) 34 (2444)
1000

(Rate per 100 000 population per year)

TB case notifications, 20 16
800
Total cases notified 27 353
Total new and relapse 27 353 600

Incidence
% tested with rapid diagnostics at time of diagnosis
% with known HIV status 100% 400
% pulmonary 88%
% bacteriologically confirmed among pulmonary 58% 200

Universal health coverage and social protection 0

TB treatment coverage (notified/estimated incidence), 2016 81% (62110) 2000 2004 2008 2012 2016
TB patients facing catastrophic total costs
Notified, new and relapse Incidence
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.17 (0.110.24) Incidence (HIV+TB only)

TB/HIV care in new and relapse TB patients, 20 16 Notified cases by age group and sex, 2016

Number (%) 65

Patients with known HIV-status who are HIV-positive 18 327 67% 5564
on antiretroviral therapy 15 761 86%
4554

Drug-resistant TB care, 20 16 3544

New cases Previously treated cases Total numberc 2534
Estimated MDR/RR-TB cases among 1 300
notified pulmonary TB cases (9501 700) 1524

Estimated % of TB cases with 014

MDR/RR-TB 4.6% (36.2) 14% (8.920)
% notified tested for 4000 3000 2000 1000 0 1000 2000 3000 4000 5000
rifampicin resistance 5 282
Females Males
MDR/RR-TB cases tested for resistance to second-line drugs 301
Laboratory-confirmed cases MDR/RR-TB: 572, XDR-TB: 5
Patients started on treatmentd MDR/RR-TB: 397, XDR-TB: 5 100

Treatment success rate and cohort size 80

Treatment success rate (%)

Success Cohort
New and relapse cases registered in 2015 81% 26 990 60

Previously treated cases, excluding relapse, registered in 2015 70% 1 235

40
HIV-positive TB cases registered in 2015 79% 18 027
MDR/RR-TB cases started on second-line treatment in 2014 51% 381
20
XDR-TB cases started on second-line treatment in 2014 0

0
TB preventive treatment, 20 16
2000 2003 2006 2009 2012 2015
% of HIV-positive people (newly enrolled in care) on preventive treatment 73%
% of children (aged < 5) household contacts of bacteriologically-confirmed New and relapse Retreatment, excluding relapse
TB cases on preventive treatment 63% (5869) HIV-positive MDR/RR-TB XDR-TB

TB financing, 20 17 40
National TB budget (US$ millions) 18
Funding source: <1% domestic, 100% international, 0% unfunded
Total budget (US$ millions)

30

20

10

Data are as reported to WHO. Estimates of TB and MDR/RR-TB burden are produced by WHO in consultation
with countries. Estimates are rounded and totals are computed prior to rounding. 0
a
Ranges represent uncertainty intervals. 2013 2014 2015 2016 2017
b
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin.
c
Includes cases with unknown previous TB treatment history.
d
Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed. Funded domestically Funded internationally Unfunded

214 GLOBAL TUBERCULOSIS REPORT 2017 Data for all countries and years can be downloaded from [Link]/tb/data
 INDICATORS IN THE SUSTAINABLE DEVELOPMENT GOALS ASSOCIATED WITH TB INCIDENCEa

30 30
HIV prevalence Population
(% of population aged living below the
1549 years) international
poverty line
0
(% of population) 0
2000 2015 2000 2015

10 30
Diabetes Population
prevalence covered by social
(% of population protection floors/
aged 18 years) systems
! females ! males (% of population)
0 0
2000 2015 2000 2015

10 50
Alcohol use Prevalence of
disorders, 12 undernourishment
month prevalence (% of population)
(% of population
aged 15 years)
0 0
! females ! males 2000 2015 2000 2015

50 40
Smoking Access to
prevalence clean fuels and
(% of population technologies
aged 15 years) for cooking
! females ! males (% of population)
0 0
2000 2015 2000 2015

200 3000
Health GDP per capita,
expenditure per PPPb
capita, PPPb (constant 2011
(constant 2011 international $)
international $)
0 0
2000 2015 2000 2015

60 50
Out-of- GINI index
pocket health (0 = perfect equality,
expenditure 100 = perfect
inequality)
(% of total
expenditure on
health) 0 0
2000 2015 2000 2015

30
Coverage of Population
essential health living in slums
services (% of urban
(based on 16 tracer population)
indicators including
TB treatment) 0
2000 2015 2000 2015

Targets for reductions in TB incidence and TB deaths set in WHOs End TB Strategy and the United Nations Sustainable Development Goals (SDGs)
are ambitious. Achieving them requires progress in reducing health-related risk factors for TB infection and disease, as well as broader social and
economic determinants of TB infection and disease. WHO has developed a TB-SDG monitoring framework that comprises 14 indicators under seven
SDGs for which there is evidence of an association with TB incidence. Further details are provided in Chapter 2.

a
Data sources: SDG indicators database, The World Bank, World Health Organization. Missing values and empty boxes indicate data not available in these data sources.
b
GDP = gross domestic product; PPP = purchasing power parity

Data for all countries and years can be downloaded from [Link]/tb/data GLOBAL TUBERCULOSIS REPORT 2017 215